Products & Services · Total revenues

IMDELLTRA/IMDYLLTRA — Total revenues

Amgen IMDELLTRA/IMDYLLTRA — Total revenues increased by 218.5% to $258.00M in Q1 2026 compared to the prior quarter. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2025
Last reportedQ1 2026
Rolls up toTotal Revenue

How to read this metric

An increase indicates successful market penetration and growing clinical demand for the therapy, while a decrease may signal competitive pressure or changes in treatment guidelines.

Detailed definition

This metric represents the total net sales generated from the commercialization of the Imdelltra (tarlatamab) therapeuti...

Peer comparison

Comparable to revenue metrics for specific high-growth oncology assets or newly launched specialty drugs at other major biotechnology and pharmaceutical companies.

Metric ID: amgn_segment_imdelltra_imdylltra_total_revenues

Historical Data

2 periods
 Q1 '25Q1 '26
Value$81.00M$258.00M
QoQ Change—+218.5%
YoY Change—+218.5%
Range$81.00M – $258.00M
Avg YoY Growth+218.5%
Median YoY Growth+218.5%

Similar Metrics at Other Companies

AbbVie logo
AbbVieABBVView metric
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMYView metric
Gilead Sciences logo
Gilead SciencesGILDView metric
Johnson & Johnson logo
Johnson & JohnsonJNJView metric
Johnson & Johnson logo
Johnson & JohnsonJNJView metric
AbbVie logo
AbbVieABBVView metric

Frequently Asked Questions

What is Amgen's imdelltra/imdylltra — total revenues?
Amgen (AMGN) reported imdelltra/imdylltra — total revenues of $258.00M in Q1 2026.
What does imdelltra/imdylltra — total revenues mean?
Total net sales generated from the Imdelltra oncology therapeutic product.